Key Facts

Invested since 2020
Based in Brandenburg

About the company

Aignostics, a spin-off from Charité – Universitätsmedizin Berlin and the Berlin Institute of Health, is pioneering computational pathology for pharmaceutical research and diagnostics. Its proprietary “Explainable AI” platform draws on research from Fraunhofer Society, Charité, and TU Berlin to overcome the typical “black-box” problem of AI in pathology. Aignostics’ focus lies on developing bespoke AI models for clinical trials and CDx development.

Do you want to

know more about this company?

Zum Artikel

Tilmann Petersen Investment Manager

Tilmann PetersenInvestment Manager

Aignostics in the news

Zum Artikel

News

29. October 2024

Aignostics Secures $34 Million Series B to Enhance Precision Medicine with AI

Zum Artikel

News

15. September 2022

Aignostics Raises €14m Series A to Advance AI-powered Pathology

Zum Artikel

News

28. August 2020

Aignostics raises €5m Seed Round to advance AI-powered pathology

More startups from Life Sciences